Big Pharma is vacating infectious diseases research to chase more lucrative segments like oncology and diabetes. This has left behind a gaping void. A set of Indian companies are diving in—Wockhardt, Orchid Pharma and Bugworks. A successful antibiotic drug can change their fortunes. Big Pharma is vacating infectious diseases research to chase more lucrative segments like oncology and diabetes. This has left behind a gaping void. A set of Indian companies are diving in—Wockhardt, Orchid Pharma and Bugworks. A successful antibiotic drug can change their fortunes. by Soban News (international And National News)
